Knock, thank you, agree with everything you say, we will sell, how much is yet to be seen, but bottom line is we are more than COVID which has paid the bills (placing) and put us in a good position with our non COVID products. Long term, time will tell
agree U, they'll be a small window they can delay the RNS which it looks like they are doing. Last years was early October, I think they only have a week or so before they are bound to release their EOY statement.
GDR is not a B2C business unlike others like NCYT. They are a B2B and their strategy is to partner in high volume markets outside of the UK. This depends on approvals for both India and US. They now have SA and will start selling there now and we should have the update shortly, most likely in the year end results.
They have developed a POC solution which is undergoing final trials and should have its approvals early next year. I suspect they'll beat most of the smoke and mirror companies out there, but the market is large and different POC solutions are required for different parts of the market.
Some may disagree with this strategy which is absolutely their right. What's not their right is to be derogatory about the competence of people trying to make a difference. If only there were more people in this world prepared to try rather than complain from behind their firewall.
RE: South Africa Sales Next Week?23 Oct 2020 17:09
Cwalsh, they won't reply, I am sure they get requests for information every day these days and they'll be weary of releasing information that isn't in the public domain. No news is no news. If there was anything that suggested something wasn't going to pan out as stated to the public, they are legally bound to announce it. Bad news has to be delivered as quickly as good news.
Can we please stop the continual defamation of peoples characters. Shame on you. Use of words like incompetent is incredibly disrespectful to companies and individuals trying to make a difference. Shame on you.
This is what I like about this business, a number of strings to its bow and what a time to be making 'technical' masks. 5m production capacity a month with a textile that is protected with its own IP and distinct from the competition. Long term value too beyond the current pandemic. Nice.
The two companies know each other, they have the same past, surely the approved test Epistem offer as a service is the Genedrive test, even if its under some preferential agreement to share performance data.
BB, nice summary, the other big difference between GDR and NCYT is that they are all about selling to customers, GDR isn't. GDR is about selling to partners who sell to customers. We need the likes of BC or Sysmex to make our market. All of the current tests GDR has for HCV and AIHL go via a commercial partner. Apart from DOD which is direct. I suspect the sysmex and BC are looking for a few very large contracts rather than selling to all comers. It sort of slows the process, regulatory, pitch, then evaluation.
Trading update shortly, I believe you can delay RNS'ing information if it coincides / is close to the dates a business is due to update the market on substantially similar events. So let's see what the trading update brings us?